Get the Stockscreener App
9.03
1.31%
-0.12
Cullinan Therapeutics Inc stock is traded at $9.03, with a volume of 320.61K.
It is down -1.31% in the last 24 hours and down -13.34% over the past month.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.
See More
Previous Close:
$9.15
Open:
$9.19
24h Volume:
320.61K
Relative Volume:
0.64
Market Cap:
$525.80M
Revenue:
-
Net Income/Loss:
$-153.16M
P/E Ratio:
-2.4472
EPS:
-3.69
Net Cash Flow:
$-134.48M
1W Performance:
-5.25%
1M Performance:
-13.34%
6M Performance:
-49.89%
1Y Performance:
-47.10%
1-Day Range:
$8.92
$9.28
1-Week Range:
$8.92
$9.825
52-Week Range:
$8.92
$30.19
Cullinan Therapeutics Inc Stock (CGEM) Company Profile
Name
Cullinan Therapeutics Inc
Sector
Industry
Phone
617-410-4650
Address
ONE MAIN STREET, CAMBRIDGE
Compare CGEM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
9.03 | 525.80M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Cullinan Therapeutics Inc Stock (CGEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-24-24 | Initiated | UBS | Buy |
| May-01-24 | Initiated | Stifel | Buy |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Feb-15-24 | Initiated | Wedbush | Outperform |
| Jun-15-23 | Initiated | TD Cowen | Outperform |
| Nov-21-22 | Initiated | BTIG Research | Buy |
| Apr-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-02-21 | Initiated | Evercore ISI | Outperform |
| Feb-02-21 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-02-21 | Initiated | SVB Leerink | Outperform |
| Feb-01-21 | Initiated | H.C. Wainwright | Buy |
View All
Cullinan Therapeutics Inc Stock (CGEM) Latest News
Prepare Yourself for Liftoff: Cullinan Therapeutics Inc (CGEM) - SETE News
CULLINAN ONCOLOGY, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com
Cullinan Therapeutics (NASDAQ:CGEM) Reaches New 12-Month LowHere's Why - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Average Rating of "Buy" by Analysts - MarketBeat
FY2024 Earnings Estimate for CGEM Issued By Leerink Partnrs - MarketBeat
What is Leerink Partnrs’ Forecast for CGEM FY2024 Earnings? - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of “Buy” by Brokerages - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Sees Strong Trading VolumeWhat's Next? - MarketBeat
What is Leerink Partnrs’ Estimate for CGEM Q1 Earnings? - Defense World
Ratio Revelations: Cullinan Therapeutics Inc (CGEM)’s Financial Metrics in the Spotlight - The Dwinnex
CGEM Stock Sees Decline of Approximately -5.74% in Last Five Days - Knox Daily
Cullinan CEO talks autoimmune pivot, upcoming lupus readout and his 'thriller or killer' approach - Fierce Biotech
SG Americas Securities LLC Has $283,000 Stock Holdings in Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
HC Wainwright Has Bearish Outlook for CGEM FY2025 Earnings - MarketBeat
Equities Analysts Issue Forecasts for CGEM Q1 Earnings - MarketBeat
HC Wainwright Brokers Decrease Earnings Estimates for CGEM - Defense World
HC Wainwright Boosts Cullinan Therapeutics (NASDAQ:CGEM) Price Target to $33.00 - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up Following Analyst Upgrade - MarketBeat
Q1 Earnings Forecast for CGEM Issued By HC Wainwright - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Cullinan reports zipalertinib study met primary endpoint - MSN
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Cullinan Therapeutics Reveals Next-Gen Pipeline Details at Major Biotech Conference - StockTitan
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade - Defense World
Cullinan/Taiho’s Zipalertinib Stands To Benefit From A Clear Market - Citeline
Cullinan Management Achieves Milestone in Cancer Trial - TipRanks
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Shares Bought by JPMorgan Chase & Co. - Defense World
Cullinan Therapeutics Says Zipalertinib Trial Met Primary Endpoint -January 29, 2025 at 04:38 am EST - Marketscreener.com
Cullinan Reveals Update On REZILIENT1 Trial Data For Zipalertinib In Non-Small Cell Lung Cancer - RTTNews
Game-Changing Lung Cancer Drug Shows Promise: New Hope for EGFR Mutation Patients - StockTitan
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics Announce Primary Endpoint Met in Phase 2b Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy - PR Newswire
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock Position Decreased by Assenagon Asset Management S.A. - Defense World
Reviewing Repligen (NASDAQ:RGEN) and Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Average Rating of “Buy” from Analysts - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Hits New 52-Week LowHere's What Happened - MarketBeat
Harbor Capital Advisors Inc. Purchases 9,385 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3%Should You Sell? - MarketBeat
Cullinan Therapeutics’ CLN-978 And Zipalertinib Look Promising In NSCLC (NASDAQ:CGEM) - Seeking Alpha
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline (NASDAQ:CGEM) - Seeking Alpha
Jennifer Michaelson Sells 4,000 Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics' chief scientific officer sells shares worth $50,040 - Investing.com
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Down 5.4%What's Next? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Sees Large Growth in Short Interest - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap UpWhat's Next? - MarketBeat
Cullinan Therapeutics Inc Stock (CGEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):